[go: up one dir, main page]

ZA200604724B - Methods for suppressing an immune response or treating a proliferative disorder - Google Patents

Methods for suppressing an immune response or treating a proliferative disorder

Info

Publication number
ZA200604724B
ZA200604724B ZA200604724A ZA200604724A ZA200604724B ZA 200604724 B ZA200604724 B ZA 200604724B ZA 200604724 A ZA200604724 A ZA 200604724A ZA 200604724 A ZA200604724 A ZA 200604724A ZA 200604724 B ZA200604724 B ZA 200604724B
Authority
ZA
South Africa
Prior art keywords
substituted
treating
subject
suppressing
methods
Prior art date
Application number
ZA200604724A
Other languages
English (en)
Inventor
Joel Moss
Arnold Kristof
Original Assignee
Us Gov Health & Human Serv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Gov Health & Human Serv filed Critical Us Gov Health & Human Serv
Publication of ZA200604724B publication Critical patent/ZA200604724B/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/28Compounds containing heavy metals
    • A61K31/282Platinum compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4738Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/14Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrane Compounds (AREA)
ZA200604724A 2003-12-09 2006-06-08 Methods for suppressing an immune response or treating a proliferative disorder ZA200604724B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US52834003P 2003-12-09 2003-12-09

Publications (1)

Publication Number Publication Date
ZA200604724B true ZA200604724B (en) 2010-01-27

Family

ID=34676839

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200604724A ZA200604724B (en) 2003-12-09 2006-06-08 Methods for suppressing an immune response or treating a proliferative disorder

Country Status (16)

Country Link
US (2) US8044057B2 (xx)
EP (1) EP1694331B8 (xx)
JP (1) JP2007513962A (xx)
KR (1) KR20060123463A (xx)
CN (1) CN1889958A (xx)
AT (1) ATE447957T1 (xx)
AU (1) AU2004296868B2 (xx)
BR (1) BRPI0417498A (xx)
CA (1) CA2546920A1 (xx)
DE (1) DE602004024115D1 (xx)
IL (1) IL176214A0 (xx)
MX (1) MXPA06006651A (xx)
RU (1) RU2006124421A (xx)
TR (2) TR200604485T1 (xx)
WO (1) WO2005056014A1 (xx)
ZA (1) ZA200604724B (xx)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE538794T1 (de) 1999-01-13 2012-01-15 Bayer Healthcare Llc Gamma carboxyarylsubstituierte diphenylharnstoffverbindungen als p38 kinasehemmer
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
SI1478358T1 (sl) 2002-02-11 2013-09-30 Bayer Healthcare Llc Sorafenib tozilat za zdravljenje bolezni, značilnih po abnormalni angiogenezi
EP1626714B1 (en) 2003-05-20 2007-07-04 Bayer Pharmaceuticals Corporation Diaryl ureas for diseases mediated by pdgfr
EP1663978B1 (en) 2003-07-23 2007-11-28 Bayer Pharmaceuticals Corporation Fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions
US20090305236A1 (en) * 2005-05-11 2009-12-10 Genetic Technologies Limited Methods of enriching fetal cells
CA2626742A1 (en) * 2005-10-21 2007-04-26 Exelixis, Inc. Pyrazolo-pyrimidines as casein kinase ii (ck2) modulators
CU23511B6 (es) * 2006-02-28 2010-04-13 Biorec B V Combinación farmacéutica para el tratamiento y/o quimiosensibilización de tumores refractarios a drogas anticancerígenas
EP1834636A1 (en) * 2006-03-08 2007-09-19 Sahajanand Medical Technologies PVT. ltd Compositions comprising porous articles and uses in implantable medical devices
US20100130597A1 (en) * 2007-07-06 2010-05-27 The United State Of America, As Represented By The Secretary Of The Dept Of Health And Human Service Dna-pkcs modulates energy regulation and brain function
WO2010093419A1 (en) 2009-02-11 2010-08-19 Merck Patent Gmbh Novel amino azaheterocyclic carboxamides
AU2010281503B2 (en) 2009-08-07 2016-01-28 Merck Patent Gmbh Novel azaheterocyclic compounds
CN101849934B (zh) * 2010-05-25 2011-11-09 苏州大学 一种磷脂酰肌醇-3-激酶抑制剂及其应用
ES2729754T3 (es) 2010-07-29 2019-11-06 Merck Patent Gmbh Carboxamidas azaheterocíclicas de aminas cíclicas
UA110113C2 (xx) 2010-07-29 2015-11-25 Біциклічні азагетероциклічні карбоксаміди
PL2643313T3 (pl) 2010-11-24 2017-03-31 Merck Patent Gmbh Azetydyny chinazolino-karboksyamidowe
US8530470B2 (en) 2011-04-13 2013-09-10 Astrazeneca Ab Chromenone derivatives
PT2705029T (pt) 2011-05-04 2019-02-01 Rhizen Pharmaceuticals S A Novos compostos como moduladores de proteína quinases
SG10201606301YA (en) 2011-09-12 2016-09-29 Merck Patent Gmbh Novel imidazole amines as modulators of kinase activity
SI2755958T1 (sl) 2011-09-12 2017-12-29 Merck Patent Gmbh Aminopirimidinski derivati za uporabo kot modulatorji kinazne aktivnosti
PT2794571T (pt) 2011-12-22 2017-02-07 Merck Patent Gmbh Novas carboxamidas heterocíclicas como moduladores da atividade de quinase
CN104507479B (zh) * 2012-03-06 2017-08-18 伊利诺伊大学评议会 通过联合治疗的半胱天冬酶‑3酶原激活
ES2807539T3 (es) 2012-11-16 2021-02-23 Merck Patent Gmbh Derivados de imidazol-piperidinilo como moduladores de la actividad de quinasa
US9580443B2 (en) 2012-11-16 2017-02-28 Merck Patent Gmbh Heterocyclic derivatives as modulators of kinase activity
ES2821102T3 (es) 2012-11-29 2021-04-23 Merck Patent Gmbh Derivados de azaquinazolincarboxamida
MX362905B (es) 2013-03-04 2019-02-25 Astrazeneca Ab Tratamiento de combinacion.
US9458134B2 (en) 2013-03-11 2016-10-04 Merck Patent Gmbh Heterocycles as modulators of kinase activity
SG11201608189WA (en) 2014-04-03 2016-10-28 Merck Patent Gmbh Combinations of cancer therapeutics
CN108929329B (zh) * 2017-05-24 2020-12-11 中国医学科学院药物研究所 2-氮杂环-5-三氟甲基-8-硝基苯并(硫代)吡喃-4-酮类化合物
CN107641109B (zh) * 2017-10-16 2019-05-24 厦门大学 一种类黄酮化合物及其制备方法和应用
CN107602520B (zh) * 2017-10-16 2019-06-14 厦门大学 一种含哌嗪环的类异黄酮化合物及其制备方法和应用
SG11202004384YA (en) 2017-11-17 2020-06-29 Univ Illinois Cancer therapy by degrading dual mek signaling
CA3114385A1 (en) 2018-10-05 2020-04-09 The Board Of Trustees Of The University Of Illinois Combination therapy for the treatment of uveal melanoma
IL283639B2 (en) 2018-12-20 2024-06-01 Amgen Inc Kif18a inhibitors
CN114980976A (zh) 2019-11-27 2022-08-30 锐新医药公司 共价ras抑制剂及其用途
AU2021376892A1 (en) 2020-11-16 2023-06-29 Merck Patent Gmbh Kinase inhibitor combinations for cancer treatment
EP4334324A1 (en) 2021-05-05 2024-03-13 Revolution Medicines, Inc. Covalent ras inhibitors and uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN164232B (xx) 1986-04-11 1989-02-04 Hoechst India
US5284856A (en) 1988-10-28 1994-02-08 Hoechst Aktiengesellschaft Oncogene-encoded kinases inhibition using 4-H-1-benzopyran-4-one derivatives
US5703075A (en) 1988-12-21 1997-12-30 Pharmacia & Upjohn Company Antiatherosclerotic and antithrombotic 1-benzopyran-4-ones and 2-amino-1,3-benzoxazine-4-ones
FI912995A7 (fi) * 1988-12-21 1991-06-19 Upjohn Co Antiateroskleroottisia ja antitromboottisia 1-bentsopyran-4-oneja ja 2 -amino-1,3-bentsoksatsin-4-oneja
US20030050692A1 (en) 2000-12-22 2003-03-13 Avantec Vascular Corporation Delivery of therapeutic capable agents

Also Published As

Publication number Publication date
AU2004296868A1 (en) 2005-06-23
TR200808208T1 (tr) 2008-12-22
KR20060123463A (ko) 2006-12-01
BRPI0417498A (pt) 2007-05-29
US20070173514A1 (en) 2007-07-26
ATE447957T1 (de) 2009-11-15
TR200604485T1 (tr) 2007-01-22
US20120039903A1 (en) 2012-02-16
CA2546920A1 (en) 2005-06-23
EP1694331B1 (en) 2009-11-11
DE602004024115D1 (de) 2009-12-24
WO2005056014A8 (en) 2006-08-31
IL176214A0 (en) 2006-10-05
WO2005056014A1 (en) 2005-06-23
RU2006124421A (ru) 2008-01-20
JP2007513962A (ja) 2007-05-31
EP1694331A1 (en) 2006-08-30
MXPA06006651A (es) 2006-08-11
AU2004296868B2 (en) 2010-11-25
US8044057B2 (en) 2011-10-25
EP1694331B8 (en) 2010-02-24
CN1889958A (zh) 2007-01-03

Similar Documents

Publication Publication Date Title
IL176214A0 (en) Methods for suppressing an immune response or treating a proliferative disorder
DK1539700T3 (da) 8-hydroxyquinolin-derivater
JP2016539180A5 (xx)
NZ591449A (en) Picolinamide derivatives as kinase inhibitors
NO20021358D0 (no) Alkylendiamin-substituerte heterocykler
BRPI0411365A (pt) derivados de aminopiridina
ATE517882T1 (de) Chinolinderivate
MX2009008338A (es) Compuestos de piridopirimidinona de utilidad en el tratamiento de enfermedades o condiciones patologicas mediadas por los canales de sodio.
EA200501820A1 (ru) Терапевтические средства для лечения боли
BR0207846A (pt) Derivados heterocìclicos para o tratamento de câncer e outras doenças proliferativas
MX2023000382A (es) Inmunomoduladores heterocíclicos.
TW200612954A (en) Anti-angiogenesis methods
RU2011100106A (ru) Замещенные бензимидазолы для лечения нейрофиброматоза
DE60202682D1 (de) Chinoline derivate und ihre anwendung als antitumor agentien
WO2001080813A3 (en) Methods for preventing and treating alopecia induced by chemotherapy or radiotherapy
WO2004066952A3 (en) Benzoxazole, benzothiazole, and benzimidazole derivatives for the treatment of cancer and other diseases
NO20076075L (no) 4-anilino-3-kinolinkarbonitriler for behandling av cancer
TNSN08093A1 (en) Quinoline derivatives and use as antitumor agents
NO20071052L (no) Fremgangsmater for behandling av proliferative hudsykdommer ved bruk av karbazolderivater
ATE398452T1 (de) 6-aryl-7-halo-imidazoä1,2-aüpyrimidine als mittel gegen krebs
DK1553938T3 (da) Anvendelse af epothilonderivater til behandling af hyperparathyroidisme
ATE471316T1 (de) Diastereoselektives syntheseverfahren mit 6-brom- 4-(3-chlorphenyl)-2-methoxychinolin
ATE435853T1 (de) Prostaglandinanaloga
TH70455A (th) ซัลโฟแนมีด ซับสทิทิวเทด อิมิดาโซควิโนลีน
MX2012006897A (es) Compuestos heterociclicos como inhibidores de janus cinasa.